Last10K.com

Enliven Therapeutics, Inc. (ELVN) SEC Filing 10-Q Quarterly Report for the period ending Friday, June 30, 2023

Enliven Therapeutics, Inc.

HISTORY TOOLS
CIK: 1672619 Ticker: ELVN

Exhibit 99.1

 

LOGO

Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results

Successfully completed merger with Imara Inc., trading under the new ticker symbol on Nasdaq, “ELVN”

Dosed first patient in Phase 1 study of ELVN-002 in patients with HER2-altered non-small cell lung cancer (NSCLC) and other solid tumors

Enrollment progressing in Phase 1 trial with ELVN-001 in chronic myeloid leukemia (CML)

Ended the first quarter 2023 with cash and cash equivalents of approximately $292 million, which is expected to provide cash runway into early 2026

BOULDER, Colo., May 11, 2023 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

“2023 is off to a strong start with the successful completion of our merger with Imara Inc. and the concurrent private financing, dosing of the first patient in the Phase 1 study of ELVN-002, continued progression of enrollment in our Phase 1 trial for ELVN-001, and good progress on our discovery pipeline,” said Sam Kintz, MBA, Enliven’s Co-founder and President and Chief Executive Officer. “2023 is a critical year of execution for us as our parallel lead programs advance ahead of expected Phase 1a data for both programs in 2024.”

Recent Business Highlights and Upcoming Milestones

Research and Development Highlights

 

  •  

ELVN-002: Dosed the first patient in the Phase 1 clinical trial evaluating ELVN-002 in people with cancers harboring an abnormal HER2 gene (NCT05650879). ELVN-002 is a CNS penetrant, selective and irreversible HER2 inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in NSCLC, for which there are currently no approved small molecule inhibitors. The Company expects to share initial safety and efficacy data from the Phase 1a study in 2024.

 

  •  

ELVN-001: Continued progress in the dose escalation portion of the Phase 1 clinical trial evaluating ELVN-001 in adults with CML (NCT05304377). The Company expects to share initial safety and efficacy data from the Phase 1a study in 2024.

 

  •  

Pipeline: Progress toward nominating a product candidate for a third program, which is expected in the second quarter of this year. Enliven is also actively pursuing multiple additional early-stage discovery programs.

The following information was filed by Enliven Therapeutics, Inc. (ELVN) on Thursday, May 11, 2023 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Enliven Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Enliven Therapeutics, Inc..

Continue

Assess how Enliven Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Enliven Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Other
Filter Subcategory:
All
Expense
Product
Cash Flow
Shares
Other
Inside Enliven Therapeutics, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (Deficit)
Condensed Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (Deficit) (Parenthetical)
Condensed Consolidated Statements Of Operations And Comprehensive Loss (Unaudited)
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (Tables)
Accrued Expenses And Other Current Liabilities - Summary Of Accrued Expenses And Other Current Liabilities (Details)
Commitments And Contingencies
Common Stock
Common Stock (Tables)
Common Stock - Additional Information (Details)
Common Stock - Following Shares Of Common Stock Reserved For Future Issuance (Details)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments (Tables)
Fair Value Of Financial Instruments - Schedule Of Financial Assets Measured At Fair Value On A Recurring Basis (Details)
Leases
Leases (Tables)
Leases - Additional Information (Details)
Leases - Summary Of Future Minimum Lease Payments Under Operating Sublease (Details)
Marketable Securities
Marketable Securities (Additional Information) (Details)
Marketable Securities (Tables)
Marketable Securities - Schedule Of Available-For-Sale Marketable Securities (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Anti Dilutive Potential Common Shares Excluded From Computation Of Diluted Net Loss Per Share (Details)
Net Loss Per Share - Schedule Of Basic And Diluted Net Loss Per Common Share (Details)
Organization, Description Of Business And Liquidity
Organization, Description Of Business And Liquidity - Additional Information (Details)
Preferred Stock And Convertible Preferred Stock
Preferred Stock And Convertible Preferred Stock (Tables)
Preferred Stock And Convertible Preferred Stock - Additional Information (Details)
Preferred Stock And Convertible Preferred Stock - Schedule Of Convertible Preferred Stock And Liquidation (Details)
Property And Equipment, Net
Property And Equipment, Net (Tables)
Property And Equipment, Net - Additional Information (Details)
Property And Equipment, Net - Schedule Of Property And Equipment, Net (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Details)
Stock-Based Compensation - Summary Of Restricted Stock Award And Restricted Stock Units Activity (Details)
Stock-Based Compensation - Summary Of Stock Option Activity (Details)
Stock-Based Compensation - Summary Of Stock-Based Compensation Expense (Details)
Stock-Based Compensation - Summary Of Stock-Based Compensation Fair Value Assumptions (Details)
Subsequent Events
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Additional Information (Details)
The Merger
The Merger (Tables)
The Merger - Additional Information (Details)
The Merger - Schedule Of Recapitalization The Company Obtained The Assets And Liabilities (Details)

Material Contracts, Statements, Certifications & more

Enliven Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Exhibit 32.2: Section 1350 Certification
Ticker: ELVN
CIK: 1672619
Form Type: 10-Q Quarterly Report
Accession Number: 0000950170-23-041349
Submitted to the SEC: Thu Aug 10 2023 4:16:58 PM EST
Accepted by the SEC: Thu Aug 10 2023
Period: Friday, June 30, 2023
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/elvn/0000950170-23-041349.htm